论文部分内容阅读
目的观察比较吉非替尼与含铂方案的常规化疗治疗晚期非小细胞肺癌(NSCLC)的疗效.方法选取呼吸科晚期NSCLC患者,常规化疗组22例,吉非替尼组15例,观察治疗效果及不良反应.结果37例可评价疗效的晚期NSCLC患者中,化疗组:CR 0例,PR 4例,SD 8例,PD 10例,缓解率18.18%(4/22),疾病控制率54.55%(12/22);吉非替尼组:CR 1例,PR 5例,SD 7例,PD 2例,缓解率40.00%(6/15),疾病控制率86.67%(13/15);不良反应主要是骨髓抑制、消化道反应及皮疹,在化疗组和吉非替尼组的发生率分别是72.73%、77.27%、13.64%及6.67%、40.00%、66.67%.结论吉非替尼对晚期NSCLC有良好的疗效,且安全性高,为肺癌的治疗提供了新的途径.“,”Objective To observe the efficacy of gefitinib and chemotherapy in treatment for advanced NSCLC.Methods 37 cases are selected and divided into two groups,gefitinib group(15 cases) and chemotherapy group(22 cases).Results Chemotherapy group got 18.18% remission rate and 54.55% disease control rate. Gefitinib group got 40.00% remission rate and 86.67% disease control rate.The major adverse reaction were bone marrow suppression,gastrointestinal reaction and skin rash,and the incidence rates were 72.73%,77.27%,13.64%in chemotherapy group and 6.67%,40.00%,66.67% in gefitinib group,respectively.Conclusion Gefitinib showed better efficacy and with less side effect.It is an effective treatment option for advanced NSCLC.